Advancements in Immunotherapy for Hepatocellular Carcinoma: EMERALD-3 Trial Results

Immunotherapy hepatocellular carcinoma treatment has taken a significant step forward with positive high-level results from the EMERALD-3 Phase III trial. The addition of dual immunotherapy using AstraZeneca’s STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab) together with lenvatinib and transarterial chemoembolisation (TACE) delivered a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with TACE alone in patients with embolisation-eligible unresectable hepatocellular carcinoma.

Four-Drug Combination Delays Disease Progression

In the trial, patients receiving the STRIDE regimen plus lenvatinib and TACE experienced a clinically relevant reduction in the risk of progression or death versus TACE monotherapy. This result is especially important because most patients undergoing embolisation have historically seen disease progression or recurrence within six to ten months. The same four-drug combination also showed a promising trend toward improved overall survival (OS). A separate arm evaluating the STRIDE regimen plus TACE without lenvatinib demonstrated strong trends toward better PFS and OS, though these were not formally tested at this interim analysis. The trial continues to follow OS and other secondary endpoints in both experimental arms.

Safety Remains Consistent with Known Profiles

The safety profile of each combination was consistent with the known profiles of the individual agents, with no new safety signals identified. This supports the potential to safely combine immunotherapy hepatocellular carcinoma approaches with locoregional therapies in earlier-stage disease.

Global Trial Design Addresses Critical Unmet Need

EMERALD-3 is a randomised, open-label, multicentre Phase III trial that enrolled 760 patients with unresectable HCC eligible for embolisation across 171 centres in 22 countries. The study design integrated systemic dual immunotherapy with standard TACE, directly addressing the gap in approved systemic options for this large patient population. HCC remains the most common form of liver cancer and the third-leading cause of cancer death worldwide.

Strategic Implications for Earlier Use of Dual Immunotherapy

These results have important implications for expanding the use of the STRIDE regimen into an earlier, embolisation-eligible stage of disease. By moving dual immunotherapy forward, the regimen has the potential to delay progression, reduce the need for subsequent therapies, and improve quality of life measures that matter to health technology assessment bodies.

The findings reinforce the growing industry focus on combining immuno-oncology agents with locoregional treatments to achieve better long-term outcomes. AstraZeneca is already in discussions with global regulatory authorities regarding these EMERALD-3 results.